Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc (NASDAQ: MBOT) is a pioneer in micro-robotic medical technologies focused on revolutionizing minimally invasive procedures. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in developing autonomous surgical platforms like the LIBERTY Robotic System and Self-Cleaning Shunt technology.
Discover comprehensive coverage of MBOT's latest press releases, including clinical milestones, regulatory updates, and strategic partnerships. Our curated news collection serves as a centralized resource for tracking advancements in robotic-assisted interventions designed to reduce surgical trauma and improve patient outcomes.
Key updates include developments in patented micro-robotic platforms, financial performance reports, and innovations addressing complex surgical challenges. Bookmark this page to stay informed about MBOT's progress in creating next-generation tools that aim to transform vascular and endoscopic procedures through precision robotics.
Microbot Medical (Nasdaq: MBOT) has secured a significant new U.S. patent for its LIBERTY® Endovascular Robotic System, expanding its potential market applications. The patent covers a modular robotic surgical system with interchangeable tool-receiver units, strengthening the company's IP portfolio which now includes 12 granted patents globally and 57 pending applications.
This development could enable LIBERTY® to expand beyond its initial focus on peripheral endovascular procedures (estimated at 2.5 million annual procedures in the U.S.) to potentially reach over 6 million annual endovascular procedures. The company is currently awaiting FDA 510(k) clearance for LIBERTY®, which is notable for being the first fully disposable robotic system in its field.
Microbot Medical (Nasdaq: MBOT) has secured a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority (IIA). The funding will enhance the company's manufacturing capabilities as it prepares for the potential commercialization of its LIBERTY® Endovascular Robotic System, which is currently awaiting FDA marketing clearance.
The IIA's decision was influenced by several factors, including the target market size, competitive advantages of the single-use disposable robot, regulatory status, and expected healthcare benefits. The LIBERTY® System is currently an investigational device pending FDA 510(k) clearance and is not available for sale in the U.S.
Microbot Medical (NASDAQ:MBOT) has appointed Christina Bailey as its new Vice President of Sales to strengthen its commercial leadership ahead of the anticipated LIBERTY® Endovascular Robotic System launch. Bailey, a two-time U.S. Olympian and gold medalist, brings 20 years of medical device sales experience from prominent companies including Boston Scientific, Abbott, Stryker, and Intuitive Surgical.
As former VP of US Sales at Endologix, Bailey demonstrated success in building and scaling sales teams. She will report directly to CEO Harel Gadot and will be responsible for establishing the sales team for LIBERTY®, which is currently pending FDA 510(k) clearance.
Microbot Medical (NASDAQ: MBOT) announced its participation in the first-ever Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting in Strasbourg, France from July 16-20, 2025. The session, titled "Endovascular Robotics; the next frontier for robotic surgery," will take place on July 19th at 1:30am CEST.
The panel will be moderated by Dr. Adnan Siddiqui from the University of Buffalo and Dr. Ryan Madder from Corewell Health. CEO Harel Gadot will present an overview of the endovascular robotic market and discuss the company's LIBERTY® Endovascular Robotic System, which is currently awaiting FDA 510(k) clearance expected this quarter.
Microbot Medical (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic System, has been added to the Russell Microcap® Index effective June 30, 2025. The inclusion comes at a strategic time as the company prepares for the anticipated Q3 launch of LIBERTY, which is currently pending FDA 510(k) clearance.
The Russell Microcap® Index is part of the annual Russell US Indexes reconstitution, which captures the 4,000 largest US stocks based on market capitalization. Russell indexes serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, and are widely used by investment managers and institutional investors.
Microbot Medical (Nasdaq: MBOT) has strengthened its commercial leadership team with key appointments ahead of the anticipated LIBERTY® Endovascular Robotic System launch. Allison Rosefort joins as Vice President of Marketing, bringing over 15 years of healthcare marketing experience and a track record of driving double-digit revenue growth. She will oversee downstream marketing and brand management strategies.
The company also welcomed Lisa Dobbins as Director of Human Resources and recently added Paul Mullen as Vice President of Sales. These appointments are strategically timed with the expected FDA decision on LIBERTY® in Q2 2025. The company aims to be prepared for immediate commercial launch following potential FDA clearance.
Rosefort previously served as Senior Director at Topcon Healthcare, while Dobbins joins from Integra LifeSciences where she was HR Business Partner for Global Operations and Quality.
Microbot Medical (NASDAQ: MBOT) has announced groundbreaking results from its ACCESS-PVI pivotal trial for the LIBERTY® Endovascular Robotic System. The trial, conducted at three leading U.S. medical centers, demonstrated a 100% success rate in robotic navigation across all cases (N=20), meeting the study's primary endpoint.
Key achievements include:
- 92% reduction in radiation exposure for operators
- Zero adverse device events reported
- Median robotic navigation time of 3 minutes to target
- 100% physician satisfaction rate
The study was conducted at Memorial Sloan Kettering Cancer Center, Baptist Hospital of Miami, and Brigham and Women's Hospital. The LIBERTY® system is currently pending FDA 510(k) clearance and is not yet available for sale in the U.S.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
